Glucagon-like peptide (GLP)-1, generated from the gene encoding proglucagon (Gcg) in intestinal L cells, has both insulinotropic and anorexigenic activities, underlying the clinical use of GLP-1 mimetics for the treatment of type 2 diabetes and obesity [2]. Here, GLP1R is linked to obesity disorder.